Претраживање
Приказ резултата 1-10 од 51
Clinical pharmacokinetics of methotrexate in the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma in pediatric patients / Klinička farmakokinetika metotreksata u terapiji akutne limfoblastne leukemije i ne-Hodkinovog limfoma u pedijatrijskoj populaciji pacijenata
(Beograd : Savez farmaceutskih udruženja Srbije, 2020)
High dose methotrexate (MTX) is used in therapy of acute lymphoblastic leukemia and non-Hodgkin lymphoma in pediatric patients. It acts as competitive inhibitor of dihydrofolate reductase and consequently inhibits synthesis ...
Inhibitors of tumor necrosis factor-α and mechanisms of their action / Inhibitori faktora nekroze tumora–α i mehanizmi njihovog dejstva
(Beograd : Savez farmaceutskih udruženja Srbije, 2020)
Tumor necrosis factor (TNF)-α is a proinflammatory cytokine with a role in immunity to pathogens, as well as in the pathogenesis of several autoimmune/inflammatory diseases. Biological drugs targeting this cytokine and ...
Biocompatible non-covalent complexes of chitosan and different polymers: characteristics and application in drug delivery / Biokompatibilni nekovalentni kompleksi hitozana sa različitim polimerima - svojstva i primena kao nosača lekovitih supstanci
(Beograd : Savez farmaceutskih udruženja Srbije, 2020)
The formulation of biocompatible drug carriers based on cationic biopolymer chitosan and natural or synthetic polymers represents an important research interest. Therefore, this review aims to perceive their potential in ...
Pharmaceutical care in Alzheimer's disease / Farmaceutska zdravstvena zaštita u terapiji Alchajmerove demencije
(Beograd : Savez farmaceutskih udruženja SrbijePharmaceutical Association of Serbia, 2020)
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory and cognitive function impairment as well as behavioural and psychiatric disturbances. Pharmaceutical care involves the process ...
Anti-dementia medications – fighting a losing battle? / Lekovi u lečenju demencija - unapred izgubljena bitka?
(Beograd : Savez farmaceutskih udruženja SrbijePharmaceutical Association of Serbia, 2020)
Alzheimer’s disease (AD), the most common cause of dementia, is growing health, social and economic issue because of the increasing number of sufferers, limited efficacy of available treatment options, and high total ...
Nutritional aspects of cognitive impairment / Nutritivni aspekti poremećaja kognitivnih funkcija
(Belgrade : Pharmaceutical Association of Serbia, 2020)
Many scientific arguments in this area, implicate low level of important nutrients in cognitive decline, simultaneously suggesting better nutritional status as an important goal in the management of cognitive ...
Relevance and evaluation of the benchmark dose in toxicology / Značaj i procena benchmark doze u toksikologiji
(Beograd : Savez farmaceutskih udruženja Srbije, 2020)
This paper aims to present the importance of the benchmark dose (BMD) as a point of departure (the lowest dose or concentration in the experiment that deviates from the response that differs from the normal ...
Telomere length as a biomarker of aging and diseases / Dužina telomera kao biomarker starenja i bolesti
(Beograd : Savez farmaceutskih udruženja Srbije, 2022)
As research related to healthspan and lifespan has become a hot topic, the necessity for a
reliable and practical biomarker of aging (BoA), which can provide information about mortality
and morbidity risk, along with ...
Biomarkers of dyslipidemia in patients with diabetic foot / Biomarkeri dislipidemije kod pacijenata sa dijabetesnim stopalom
(Beograd : Savez farmaceutskih udruženja Srbije, 2022)
Diabetic foot (DF) is one of the most severe complications of diabetes that significantly
reduces the quality of life and survival of patients. Besides firmly established risk factors, novel
data indicate that alterations ...
Does Pentraxin-3 contribute to the reduction of low-density lipoprotein levels by statin therapy? / Da li pentraksin -3 doprinosi sniženju koncentracije lipoproteina niske gustine i terapiji statinima?
(Pharmaceutical Association of Serbia, 2022)
Statins have been shown to decrease inflammatory markers, especially high sensitivity C reactive protein (hsCRP), in a dose-dependent manner. Pentraxin-3 (PTX3) is another important inflammatory biomarker from the pentraxin ...